Resistance related metabolic pathways for drug target identification in Mycobacterium tuberculosis

Abstract

BackgroundIncreasing resistance to anti-tuberculosis drugs has driven the need for developing new drugs. Resources such as the tropical disease research (TDR) target database and AssessDrugTarget can help to prioritize putative drug targets. Hower, these resources do not necessarily map to metabolic pathways and the targets are not involved in dormancy. In this study, we specifically identify drug resistance pathways to allow known drug resistant mutations in one target to be offset by inhibiting another enzyme of the same metabolic pathway. One of the putative targets, Rv1712, was analysed by modelling its three dimensional structure and docking potential inhibitors.ResultsWe mapped 18 TB drug resistance gene products to 15 metabolic pathways critical for mycobacterial growth and latent TB by screening publicly available microarray data. Nine putative targets, Rv1712, Rv2984, Rv2194, Rv1311, Rv1305, Rv2195, Rv1622c, Rv1456c and Rv2421c, were found to be essential, to lack a close human homolog, and to share >67 % sequence identity and >87 % query coverage with mycobacterial orthologs. A structural model was generated for Rv1712, subjected to molecular dynamic simulation, and identified 10 compounds with affinities better than that for the ligand cytidine-5′-monophosphate (C5P). Each compound formed more interactions with the protein than C5P.ConclusionsWe focused on metabolic pathways associated with bacterial drug resistance and proteins unique to pathogenic bacteria to identify novel putative drug targets. The ten compounds identified in this study should be considered for experimental studies to validate their potential as inhibitors of Rv1712.Electronic supplementary materialThe online version of this article (doi:10.1186/s12859-016-0898-8) contains supplementary material, which is available to authorized users.

An integrative, multi-omics approach towards the prioritization of Klebsiella pneumoniae drug targets

“…In line with this, previous efforts have been employed to in silico detect drug targets in the proteomes of clinically relevant bacteria such as Corynebacterium spp. 3 , Mycobacterium tuberculosis 4 – 8 , Streptococcus pneumoniae 9 , M. leprae 10 , Helicobacter pylori 11 , Clostridium botulinum 12 , 13 , Pseudomonas aeruginosa 14 , E. coli 15 and other Enterobacteriaceae family members 16 , as well as Staphylococcus epidermidis 17 . Building upon some of these genome mining works, others have successfully set out to find inhibitors of targets of interest, such as those acting on S. aureus wall teichoic acid biogenesis components (for which the identified compounds potentiated the action of β-lactams) 18 , quorum-sensing components in P. aeruginosa 19 , and histidine kinases of Shigella flexneri 20 and S. epidermidis 21 .…”

Designing novel possible kinase inhibitor derivatives as therapeutics against Mycobacterium tuberculosis: An in silico study

“…Previous studies used genome and metabolic pathway mapping to identify nine putative targets for the design of novel therapeutic agents 11 . In this study, Rv2984 was used as a target for the design of potential inhibitors against M .…”

Repurposing Novobiocin for activity against latency associatedMycobacterium tuberculosisdrug target nicotinate-nucleotide adenylyltransferase (Rv2421c)

“…Rv2421c is involved in nicotinate and nicotinamide metabolism in M. tuberculosis and has no equivalent human ortholog [7]. It is upregulated during non-growing metabolically active conditions of M. tuberculosis survival and lacks a close homolog in mice making it an attractive drug target [7]. The crystal structure of Rv2421c has been resolved and offers a unique opportunity for structure-based drug design [8].…”